← All trials
NCT01922375
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2011
- Primary completion
- Sep 1, 2012
- Completion date
- Sep 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 411
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Dong-A PharmaceuticalLead sponsor
- Inje UniversityOverall official - principal investigator
- Hallym UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Yeongnam UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Gyeongsang UniversityOverall official - principal investigator
- Inha UniversityOverall official - principal investigator
- Ewha Womans UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.